Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Dysphagia, Stroke
Interventions: tDCS; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gaucher Disease, Type 1
Interventions: Eliglustat tartrate, Imiglucerase; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Laryngeal Dystonia
Interventions: neurofeedback brain-computer interface (BCI); Device
Lead sponsor: Kristina Simonyan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
Interventions: Aldafermin, Placebo; Drug
Lead sponsor: Michael Camilleri, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Major Depressive Disorder
Interventions: SHX-001 Active low dose, Placebo, SHX-001 Active High dose; Drug
Lead sponsor: Shenox Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio

Conditions: Venous Leg Ulcer
Interventions: Membrane Wrap™, Standard of Care; Device · Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 9
States / cities: Mesa, Arizona • San Franciso, California • DeLand, Florida + 6 more

Conditions: HIV Infections
Interventions: Raltegravir and Abacavir/Lamivudine; Drug
Lead sponsor: Denver Infectious Disease Consultants, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Phoenix, Arizona • Denver, Colorado • Santa Fe, New Mexico

Conditions: HIV Infections
Interventions: HAART; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions: Neflamapimod, Placebo; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more

Conditions: Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions: Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines); Behavioral · Drug
Lead sponsor: Wayne State University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Physical Deconditioning
Interventions: Progressive Rehabilitation; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Arvada, Colorado

Conditions: Obstructive Sleep Apnea
Interventions: HFNC, Low flow oxygen by nasal cannula; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 12 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Kansas City, Kansas • Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: CBT/CMT, Control group traditional primary care; Behavioral · Other
Lead sponsor: Community Wellness Center, West Linn, OR; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Linn, Oregon

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, COBI, ATV, DRV, NRTI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more

Conditions: Anterior Cruciate Ligament Injury, ACL
Interventions: Mechanical Perturbation Training; Device
Lead sponsor: University of Delaware; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Cocaine-Related Disorders
Interventions: Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM), Placebo, Modafinil; Behavioral · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Low Back Pain, Degenerative Disc Disease, Depression, Anxiety
Interventions: Oxycodone, Morphine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Appetitive Behavior, Obesity
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Sham repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Belmont, Massachusetts • Boston, Massachusetts

Conditions: Opioid-use Disorder
Interventions: Transcranial Alternating Current Stimulation (tACS); Device
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 61 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Lupus Nephritis
Interventions: Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 17
States / cities: La Palma, California • San Leandro, California • Torrance, California + 13 more

Conditions: Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions: N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Fostering Eating After Stroke With Transcranial Direct Current Stimulation

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Brain-Computer Interfaces in Laryngeal Dystonia

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Ketamine for Major Depressive Disorder

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

Improving Physical Function in Skilled Nursing Facility Residents

Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen as a Treatment for Obstructive Sleep Apnea in Infants

Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Mechanical Perturbation Training for ACL Injury Prevention

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans

Frontoparietal Synchronization to Modulate Drug Craving in Opioid Use Disorder

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy